Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo

Imran Howell; Daniel J Bratton; Gareth Hynes; Steven W Yancey; Liam G Heaney; Ian D Pavord; Rahul Shrimanker

doi:10.1183/23120541.00196-2024

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo

ERJ Open Res. 2024 Jul 29;10(4):00196-2024. doi: 10.1183/23120541.00196-2024. eCollection 2024 Jul.

Authors

Imran Howell¹, Daniel J Bratton², Gareth Hynes¹, Steven W Yancey³, Liam G Heaney⁴, Ian D Pavord¹, Rahul Shrimanker⁵

Affiliations

¹ Oxford Respiratory NIHR BRC and Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
² Clinical Statistics, GSK, Brentford, UK.
³ Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.
⁴ Department of Respiratory Medicine, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
⁵ Bristol Academic Respiratory Unit, Bristol, UK.

Abstract

Asthma exacerbations in people treated with mepolizumab result in less peak expiratory flow reduction than placebo but similar symptom scores. Symptoms recover slower, indicating these exacerbations may be less prednisolone responsive. https://bit.ly/3xQsFRB.